With the Magellan robotic catheter eKit, physicians will now have robotic control of third party microcatheters through the existing Magellan Robotic Catheter 6F architecture. This added ability has the potential to help reduce procedure times and radiation exposure.
The Magellan robotic catheters eKit, the company’s latest addition to the family of approved Magellan robotic catheters, helps extend robotic capabilities and control throughout procedures in the peripheral vasculature.
The US FDA approval comes after multiple cases were performed with the eKit by Marc Sapoval, Hôpital Européen Georges Pompidou in Paris, France, as a part of the embolization procedures in peripheral vasculature clinical study. Sapoval successfully performed several prostate artery embolization procedures and uterine artery embolization procedures with the eKit as a part of this study.
With the FDA clearance, the eKit can now be used by physicians in the USA. “The new Magellan robotic catheter eKit is a big step forward for our robotic vascular procedures,” said Ripal Gandhi, Miami Cardiac & Vascular Institute (MCVI) in Miami, USA. “With the added robotic capabilities, we will be able to work outside of the radiation zone throughout more of the procedure and will be able to extend the stability and precision of robotic technology to the smaller microcatheters during our procedures.”
